Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    nAChR
Show Display Options
Rank Status Study
1 Completed Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
2 Completed Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
3 Completed A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Conditions: Schizophrenia;   Impaired Cognition
Intervention: Drug: EVP-6124
4 Completed Nicotinic Receptor Levels After Stopping Smoking
Condition: Nicotine Addiction
Intervention: Drug: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
5 Recruiting PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA
Condition: Measure of Uptake of XTRA in the Brain.
Intervention: Radiation: Positron Emission Tomagraphy (PET) Imaging
6 Completed Brain Imaging in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: [123] 5-I-A-85380
7 Recruiting Brain Nicotine Receptor Density in Veteran Smokers
Condition: Positron Emission Tomography
Intervention:
8 Completed Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers
Condition: Nicotine Addiction
Intervention:
9 Suspended Study of Nicotine Patches in Patients With Sarcoidosis
Condition: Pulmonary Sarcoidosis
Intervention: Drug: nicotine patch
10 Completed Anti-inflammatory Effects of GTS-21 After LPS
Conditions: Endotoxemia;   Sepsis;   Vagal Activity
Interventions: Drug: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride];   Drug: Placebo;   Drug: Lipopolysaccharide E. Coli 113:H 10:K negative
11 Completed PET Imaging of Nicotinic Acetylcholine Receptors
Conditions: Healthy Volunteers;   Nicotine Dependence;   Pharmacokinetics
Intervention:
12 Withdrawn Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
Conditions: Alzheimer's Disease;   Dementia;   Cognition
Intervention: Drug: EVP-6124
13 Terminated Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
Conditions: Alzheimer's Disease;   Dementia
Intervention: Drug: EVP-6124
14 Terminated Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Drug: EVP-6124;   Drug: Placebo
15 Terminated Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Drug: EVP-6124;   Drug: Placebo
16 Recruiting Role of SLURP-1 in Melanoma and Melanoma Stem Cells
Condition: Melanoma;
Intervention:
17 Completed Nicotine Receptor Levels and Smoking Cessation
Conditions: Smoking Cessation;   Nicotine Addiction
Intervention: Drug: Nictonie Patch, Verenacline
18 Completed
Has Results
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
Conditions: Alcohol Dependence;   Depression
Interventions: Drug: Mecamylamine;   Drug: Placebo
19 Completed
Has Results
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Conditions: Schizophrenia;   Schizoaffective Disorder;   Bipolar Disorder;   Smoking
Interventions: Drug: Varenicline;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.